NVS

NovartisD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

Execution beats on core portfolio and successful launches/approvals push revenue and margin upside; cost discipline and share buybacks support multiple expansion toward the analyst high (~$175) as investors re-rate growth optionality.

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.3.

What can break

Accelerated biosimilar/generic erosion in key markets

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $144.40 · Bull $175.00 · Bear $109.51

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-02-04 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net —

Target $153.71

Why

Momentum29 · Δ7d -14.9

Value64 · Δ7d -0.3

Sentiment40 · Δ7d -2.8

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

-14.9

Δ21d

-17.5

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.3

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-2.8

Δ21d

-0.7

Why this grade

Composite grade D. Momentum 29.1 / Value 64.5 / Sentiment 40.5

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$282.11B

Beta

0.78

Shares Out

1.83B

P/E (TTM)

18.7

P/S (TTM)

5.16

P/FCF (TTM)

31.31

Rev YoY

-0.6%

EPS YoY

-9.5%

Gross Margin

+74.6%

Op Margin

+31.0%

Net Debt

$23.79B

Current Ratio

0.85

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology